Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer), By Type (Mice, Rats), By End-User (Inpatient Settings, Community Settings), By Region and Competition, 2020-2030F

Market Overview

Global Patient-Derived Xenograft Model Market has valued at USD 2.26 Billion in 2024 and is expected to reach USD 4.00 Billion by 2030 with a CAGR of 9.98% during the forecast period. The Patient-Derived Xenograft (PDX) Model Market is experiencing a rapid expansion driven by its pivotal role in advancing cancer research and personalized medicine. PDX models, where human tumor tissues are implanted into immunodeficient mice, offer a sophisticated and clinically relevant platform for studying cancer biology and drug development.  Cancer research has come a long way in recent years, thanks to innovative techniques and models that help scientists understand disease better and develop more effective treatments. One such model gaining prominence in cancer research is the Patient-Derived Xenograft (PDX) model. PDX models are revolutionizing our approach to cancer studies, offering a more accurate representation of human tumors and enabling personalized medicine breakthroughs.

Patient-Derived Xenograft (PDX) models have gained immense popularity in the realm of preclinical research and drug development. These models, involving the transplantation of patient tumor tissue into immunodeficient mice, closely mimic the complexity of human tumors, offering invaluable insights into disease mechanisms and potential therapeutic strategies. A Patient-Derived Xenograft model involves implanting tumor tissue directly from a cancer patient into an immunodeficient mouse. This model faithfully recapitulates the tumor's genetic and molecular characteristics, as well as its growth patterns and response to therapies. By preserving the original tumor's heterogeneity and complexity, PDX models provide a reliable platform for investigating cancer biology, drug testing, and therapeutic development.  Firstly, the rising incidence of cancer worldwide has created an urgent need for more effective treatments. PDX models provide an invaluable tool for testing new cancer therapies, as they faithfully replicate the heterogeneity and complexity of human tumors, allowing researchers to assess drug efficacy and safety more accurately. Secondly, the era of personalized medicine has significantly contributed to the demand for PDX models. Tailoring treatments to individual patients based on their tumor's genetic and molecular characteristics has become a focal point in oncology. PDX models enable researchers and clinicians to predict a patient's response to specific therapies, paving the way for more targeted and effective treatment strategies.

Moreover, leading companies in the industry, including Charles River Laboratories, The Jackson Laboratory, and Crown Bioscience, are actively pursuing strategic initiatives such as partnerships, collaborations, mergers and acquisitions, and geographic expansions to enhance their service offerings and gain a competitive edge. For example, in November 2023, Charles River Laboratories announced a partnership with Aitia to jointly develop patient-derived xenograft (PDX) digital twins aimed at advancing in vivo oncology research.

Key Market Drivers

Rising Cancer Incidence and Unmet Medical Needs

One of the primary drivers behind the growth of the PDX model market is the global increase in cancer incidence. According to the World Cancer Research Fund, cancer is a leading cause of death worldwide, with new cases expected to rise by approximately 70% over the next two decades. This alarming trend has created an urgent need for more effective cancer treatments. PDX models, which faithfully replicate the complex and heterogeneous nature of human tumors, are instrumental in the development of novel therapies. They provide a platform for researchers to study various aspects of cancer, from tumor biology to drug response, ultimately contributing to the discovery of more effective treatment options. Cancer has long been one of the most significant global health challenges, with millions of lives affected each year. The Patient-Derived Xenograft model is a preclinical research tool that involves the implantation of human tumor tissues into immunodeficient mice. These mice then develop tumors that closely resemble the original human tumors in terms of genetic and molecular characteristics, heterogeneity, and growth patterns. PDX models offer several advantages over traditional cell line models, particularly in the context of rising cancer incidence and unmet medical needs. The global cancer incidence is increasing due to a number of factors, including aging populations, unhealthy lifestyles, and environmental pollution. PDX models maintain the complex mix of cell types found in patient tumors, making them an invaluable resource for studying tumor heterogeneity, disease progression, and the development of treatment resistance. This mirrors the clinical reality of cancer, where individual patients often have diverse tumor profiles.

Moreover, increasing cases of breast cancer globally. According to the data published by the American Cancer Society in 2024, there would be 310,720 new cases of invasive breast cancer and 56,500 new cases of ductal carcinoma in situ (DCIS) will be diagnosed in women. Moreover, approximately 42,250 women are projected to die from breast cancer in 2024. Increasing prevalence of cancer cases would lead to significant investment in breast cancer research and drug development, driving demand for more reliable preclinical models such as PDX models.

Advancements in PDX Technology

Continuous advancements in PDX technology have significantly improved the reliability and versatility of these models. The development of patient-derived organoids, three-dimensional cell cultures that more accurately mimic human tumors, has expanded the range of applications for PDX models. Organoids can be used to study drug responses in a high-throughput manner and are particularly valuable for precision medicine efforts. Additionally, improvements in engraftment techniques have addressed some of the challenges associated with low engraftment rates, enhancing the overall utility of PDX models. As PDX technology continues to evolve, its attractiveness to researchers and industry stakeholders continues to grow.

Traditional PDX models required immediate transplantation of patient tumor tissue into mice. However, recent advancements in cryopreservation techniques have allowed for the long-term storage of patient-derived samples. This breakthrough not only facilitates easier logistics but also enables researchers to establish a repository of PDX models representing a wide range of cancer types and subtypes. Enhancements in engraftment techniques have increased the success rates of PDX model establishment. Researchers can now transplant smaller tissue samples with higher success rates, reducing the need for large amounts of patient material. This is particularly crucial when dealing with precious or limited biopsy samples. While traditional PDX models use immunocompromised mice, recent advances have led to the development of PDX models with humanized immune systems. These models offer a more accurate representation of the interactions between tumors and the human immune system, making them invaluable for immunotherapy research and development.

Biomarker Discovery and Drug Development

PDX models offer a unique opportunity for biomarker discovery, which is essential for developing targeted cancer therapies. Researchers can study the molecular and genetic profiles of PDX tumors to identify novel biomarkers associated with drug response and resistance. This knowledge is invaluable for designing more effective, targeted therapies that improve patient outcomes. Biomarker-driven drug development is gaining momentum, and PDX models are at the forefront of these efforts. The patient-derived xenograft (PDX) model is a powerful tool for cancer research and drug development. PDX models are created by transplanting tumor cells from a patient into a mouse or other animal. This allows researchers to study the tumor in a more natural environment and to test new drugs in a more relevant setting than traditional in vitro models. PDX models are increasingly being used to discover and validate biomarkers for cancer. Biomarkers are biological molecules that can be used to identify, diagnose, or monitor a disease. PDX models can be used to identify biomarkers that are specific to a particular cancer type or that are predictive of patient response to treatment. PDX models are also being used to develop new drugs for cancer. PDX models can be used to screen new drugs for efficacy and safety. They can also be used to study the mechanisms of action of drugs and to identify drug combinations that are more effective than single drugs.

One of the most significant driving forces behind the surge in PDX model adoption is its ability to facilitate biomarker discovery. Biomarkers are measurable biological indicators that provide critical information about disease progression, response to therapy, and prognosis. Identifying and validating biomarkers is crucial in understanding disease mechanisms and tailoring treatments to individual patients. PDX models offer a unique advantage in this context as they closely replicate the molecular and cellular characteristics of human tumors, enabling researchers to study disease pathways, genetic mutations, and protein expressions within an in vivo setting.

Download Free Sample Report

Key Market Challenges

Heterogeneity and Variability

One of the primary challenges with PDX models is the inherent heterogeneity and variability of human tumors. Human cancers are highly diverse, even within the same cancer type, making it difficult to create PDX models that accurately represent all aspects of the disease. Tumor heterogeneity can result in variations in drug responses, making it challenging to predict the effectiveness of therapies based on PDX models alone. This limitation can hinder the translatability of preclinical results to clinical outcomes. Human cancers are notorious for their diversity, even among tumors of the same type or subtype. This diversity arises from variations in genetic mutations, cellular composition, microenvironmental factors, and many other intricate biological aspects. As a result, creating PDX models that faithfully represent the entirety of this heterogeneity becomes a formidable task. The challenge lies in selecting a small piece of tumor tissue from a patient, engrafting it into immunodeficient mice, and expecting it to accurately mirror the complexity of the original tumor. While PDX models do capture many aspects of this diversity, they cannot fully replicate the full spectrum of genetic mutations and cellular interactions that occur within a patient's tumor.

Time and Resource Intensity

The generation and maintenance of PDX models are time-consuming and resource-intensive processes. It can take several months to establish a single PDX model, including the initial engraftment, expansion, and characterization phases. Furthermore, PDX models require continuous monitoring and care, adding to the operational costs. This time and resource intensity can limit the scalability of PDX model studies, especially for academic and smaller research institutions with limited budgets and resources. Establishing and maintaining PDX models is a laborious and time-consuming process. It typically begins with the transplantation of patient tumor tissue into immunodeficient mice. While this initial engraftment phase can take several weeks, it represents only the beginning of a prolonged journey. PDX models require continuous monitoring, including tracking tumor growth, evaluating treatment responses, and managing the health and well-being of the mice. This ongoing care and oversight add to the operational costs and consume valuable researcher time.

Costs and Accessibility

Establishing and maintaining PDX models can be expensive, particularly for institutions with limited budgets. The costs associated with acquiring immunodeficient mice, housing and caring for them, and conducting experiments can be a barrier to entry for many researchers. Furthermore, the need for specialized equipment and expertise in handling PDX models adds to the overall costs. The high upfront investment and ongoing expenses can limit the accessibility of PDX models to a broader research community. Creating and maintaining PDX models is an expensive endeavor. It encompasses several costly components, including acquiring immunodeficient mice, housing and caring for them in controlled environments, procuring patient tumor samples, and conducting experiments. The upfront investment and ongoing operational expenses can place PDX models out of reach for many academic institutions, smaller research organizations, and emerging biotech companies with constrained budgets. The high costs associated with PDX models create a disparity in accessibility, limiting their availability primarily to well-funded research institutions and large pharmaceutical companies.

Key Market Trends

Rising Interest in Personalized Medicine

Personalized medicine, which tailors medical treatments to individual patients based on their genetic makeup and specific disease characteristics, is gaining momentum. PDX models play a pivotal role in this paradigm shift by offering a platform for testing therapies on patient-specific tumor samples. The ability to create "avatar mice" with tumors derived from individual patients allows for more accurate prediction of treatment responses, reducing the risk of adverse reactions and optimizing therapeutic outcomes. PDX models are uniquely suited to support the principles of personalized medicine. By transplanting patient tumor tissue directly into immunodeficient mice, researchers can create "avatar mice" that carry tumors derived from individual patients. These models faithfully replicate the genetic and molecular complexity of the original tumors, allowing for highly personalized preclinical testing of potential therapies. As a result, PDX models enable researchers to predict how an individual patient's tumor will respond to specific treatments, paving the way for more effective and targeted therapies.

The benefits of personalized medicine are manifold. Patients stand to gain from treatments that are not only more effective but also less likely to produce adverse side effects, as therapies can be tailored to their genetic and molecular profiles. Pharmaceutical companies benefit by increasing the success rates of clinical trials and reducing the costly late-stage failures that have plagued drug development historically.

Advances in Genomic Profiling

Genomic sequencing technologies have advanced at an astonishing pace, enabling researchers to delve deeper into the genetic and molecular underpinnings of tumors. This wealth of genomic data is being integrated into PDX model studies, allowing for a more comprehensive understanding of the genetic mutations, biomarkers, and pathways driving cancer. This integration enhances the utility of PDX models in drug development by facilitating the identification of potential therapeutic targets and predictive biomarkers. Moreover, genomic profiling has opened the door to the identification of specific biomarkers and therapeutic targets that can guide drug development. PDX models, when integrated with genomics, become powerful tools for validating these targets and predicting patient responses to novel treatments. This predictive capability is essential for reducing the attrition rates of drug candidates during clinical trials and ensuring that the right therapies reach the right patients.

Immunotherapy Revolution

Immunotherapy has emerged as a groundbreaking approach in the treatment of cancer and other diseases. PDX models are instrumental in studying the complex interactions between tumors and the immune system. Researchers are using these models to assess the efficacy of immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, and to explore novel combination therapies. PDX models are thus playing a pivotal role in advancing the field of immunotherapy. PDX models offer a unique advantage in studying immunotherapies because they closely mimic the in vivo tumor microenvironment, including the intricate interplay between tumor cells and immune cells. Researchers can use these models to assess the effectiveness of immunotherapies in a setting that faithfully replicates the complexity of human tumors. This capability is critical for optimizing immunotherapeutic strategies, predicting patient responses, and identifying potential biomarkers of immunotherapy success. One of the key factors driving the adoption of PDX models in immunotherapy research is their ability to create personalized models. Researchers can generate PDX models using patient-specific tumor samples, allowing them to test immunotherapies on tumors that closely resemble those of individual patients.

Segmental Insights

Model Type Insights

Based on the Model Type, the mice model segment emerged as the dominant player in the global market for Patient-Derived Xenograft Model. This is attributed to several key factors including Biological Relevance, Mice models have a well-established infrastructure, and mice models enable researchers to conduct longitudinal studies over an extended period, etc. Mice models closely mimic the physiological and biological aspects of human tumors, making them a preferred choice for PDX studies. The engraftment of patient tumor tissue into immunodeficient mice allows researchers to recreate the tumor microenvironment, including interactions with immune cells, stromal components, and blood vessels. This biological relevance is essential for studying disease progression and evaluating the efficacy of potential therapies.

Download Free Sample Report

Regional Insights

Based on the Region, North America emerged as the dominant region in the global Patient-Derived Xenograft Model market, holding the largest market share. This is on account of several key factors such as advanced healthcare infrastructure, Strong Research and Development Ecosystem and high regulatory acceptance. North America has a relatively high incidence of various diseases, including cancer, which necessitates intensive research efforts and the development of more effective therapies. PDX models have found particular relevance in oncology research, aligning with the region's focus on cancer treatment and drug discovery. North America boasts one of the most advanced healthcare infrastructures globally, with state-of-the-art hospitals, medical facilities, and research institutions. This robust healthcare ecosystem facilitates the diagnosis and treatment of conditions that require HGH therapy, contributing to the region's prominence in the market.

Moreover, The growth of the patient-derived xenograft (PDX) model market in North America is primarily driven by the region's advanced healthcare infrastructure, strong presence of key industry players, rising cancer prevalence, and increasing public and private investments. According to the Centers for Disease Control and Prevention (CDC), approximately 239,612 new cases of breast cancer were reported among women in the US in 2020, with around 42,273 deaths. This translates to roughly 119 new cases and 19 deaths per 100,000 women. Additionally, the Breast Cancer Organization reports that nearly 1 in 8 women (12%) in the US will develop invasive breast cancer during their lifetime. In Canada, breast cancer remains the most commonly diagnosed cancer among women and the second leading cause of cancer-related deaths. The Canadian Cancer Society estimated that about 28,600 women were diagnosed with breast cancer in 2022, making up 25% of all new cancer cases in women. This growing cancer burden underscores the demand for effective treatments, thereby boosting the PDX model market.

The patient-derived xenograft (PDX) model market in the Europe is expected to witness significant growth during the forecast period. This growth is primarily driven by the country’s stringent regulatory framework and the strong presence of leading pharmaceutical and biopharmaceutical companies. Additionally, robust government support is playing a pivotal role in fueling market expansion. Organizations such as the National Institute for Health Research (NIHR), Cancer Research UK, and other funding bodies are making substantial investments in cancer research initiatives that leverage advanced preclinical models, including PDX models. For instance, in October 2024, NIHR, in collaboration with the Office for Life Sciences (OLS), announced funding of approximately USD 14.01 million for six projects through the Invention for Innovation (i4i) program and the OLS Cancer Programme. Furthermore, growing collaboration among academic institutions, hospitals, and private sector entities within the UK’s cancer research ecosystem is enhancing the adoption of PDX models for drug development and translational research.

Recent Developments

• In August 2024, Altogen Labs, a preclinical contract research organization (CRO), announced the successful validation of 10 lung cancer xenograft models. These models are instrumental in assessing the in vivo efficacy of new therapeutic candidates for lung cancer, contributing to advancements in the diagnosis, understanding, and treatment of primary lung carcinoma.
• In May 2024, BioAtla, Inc., a clinical-stage biotechnology company, received FDA authorization for its novel antibody-drug conjugate (ADC), BA3361, which targets multiple tumor types. The company showcased the superior performance of BA3361 in both cell line-derived and patient-derived xenograft (PDX) models, including pancreatic cancer. The therapy demonstrated complete tumor regression and lower toxicity, thanks to its CAB (conditionally active biologic) selectivity.
• In March 2024, Crown Bioscience, a global CRO, announced it would present innovative findings at the AACR 2024 conference. The presentation will highlight data derived from its PDX models, which are vital for advancing preclinical oncology research and fostering the development of more precise and effective cancer therapies.
• In December 2020, Collagen Matrix, Inc., a leader in collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners ("Linden") announced the acquisition of Sunstar's Degradable Solutions . It includes the GUIDOR brand of synthetic, biodegradable medical implants. The goal of the acquisition is to increase the variety of technologies offered to clients.
• In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres and entered into partnerships with the University of Washington and the Dana-Farber Cancer Institute. Both the company's product expansion and the community working on oncology drugs benefit from this.

Key Market Players

• Charles River Laboratories Inc.
• The Jackson Laboratory
• Crown Bioscience,Inc.
• Altogen Labs
• Envigo
• WuxiAppTec
• Oncodesign
• Hera BioLabs
• XenTech
• Abnova Corporation

Report Scope:

In this report, the Global Patient-Derived Xenograft Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Patient-Derived Xenograft Model Market, By Tumor Type:

o   Lung Cancer

o   Pancreatic Cancer

o   Prostate Cancer

o   Breast Cancer

o   Other Cancer

• Patient-Derived Xenograft Model Market, By End User:

o   Inpatient Settings

o   Community Settings

• Patient-Derived Xenograft Model Market, By Type:

o   Rats

o   Mice

• Patient-Derived Xenograft Model Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Patient-Derived Xenograft Model Market.

Available Customizations:

Global Patient-Derived Xenograft Model market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Patient-Derived Xenograft Model Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com